Tumors of the Central Nervous System, Volume 4

Brain Tumors (Part 2)

  • M.A. Hayat

Part of the Tumors of the Central Nervous System book series (TCNS, volume 4)

Table of contents

  1. Front Matter
    Pages i-xxvi
  2. Introduction

    1. Front Matter
      Pages 1-1
    2. Isabelle Baldi, Hugues Loiseau
      Pages 3-13
    3. Mohit Singh, Juliette Hukin
      Pages 15-24
    4. Roberto Gaggero, Alessandro Consales, Francesca Fazzini, Maria Luisa Garrè, Pasquale Striano
      Pages 25-31
  3. Tumor to Tumor

    1. Front Matter
      Pages 33-33
    2. Marc R. Matrana, Nuhad K. Ibrahim
      Pages 35-49
    3. Xinmai Yang, Mark Cohen
      Pages 51-56
  4. Biomarkers and Diagnosis

    1. Front Matter
      Pages 57-57
    2. Luciana Oliveira de Almeida
      Pages 59-69
    3. Takamitsu Fujimaki
      Pages 71-77
    4. Matthew L. Dashnaw, Kevin A. Walter, Eleanor B. Carson-Walter
      Pages 79-86
    5. Yongping You, Ning Liu, Chunsheng Kang, Peiyu Pu, Zhen Fu
      Pages 87-93
    6. Tan Boon Toh, Yuk Kien Chong, Beng Ti Ang, Carol Tang
      Pages 95-101
    7. Filippo Alongi, Arturo Chiti, Pierina Navarria, Marta Scorsetti
      Pages 103-110
    8. Robert Pichler, Sabine Spiegl-Kreinecker, Gabriele Wurm
      Pages 111-117
  5. Imaging

    1. Front Matter
      Pages 129-129
    2. Abedelnasser Abulrob, Umar Iqbal, Boguslaw Tomanek, Danica Stanimirovic
      Pages 131-141
    3. Rubén Cárdenes, Emma Muñoz-Moreno, Rosario Sarabia-Herrero, Daniel Argibay-Quiñones, Marcos Martín-Fernández
      Pages 143-152

About this book

Introduction

This volume mainly contains information on the diagnosis, therapy, and prognosis of brain tumors. Insights on the understanding of molecular pathways involved in tumor biology are explained, which should lead to the development of effective drugs. Information on pathways (e.g., hedgehog) facilitates targeted therapies in cancer. Tumor models are also presented, which utilize expression data, pathway sensitivity, and genetic abnormalities, representing targets in cancer. For example, rat model of malignant brain tumors using implantation of doxorubicin with drug eluting beads for delivery is explained. The future of pathway-driven therapies for tumors is summarized. The importance of personalizing cancer care is emphasized. The need for supportive measures for survivors of brain cancer is pointed out, so is the quality of life monitoring. The need of rehabilitation therapy for patients with primary and metastatic brain tumors is also emphasized. Role of MicroRNA in distinguishing primary tumors from metastatic primary tumors is discussed. Advantages and limitations of chemotherapy (e.g., temozolomide and doxorubicin) are discussed. The complexity of tumor to tumor transfer is explained; examples discussed are: brain metastases from breast cancer and brain metastases fro non-small cell lung carcinoma. Identification and characterization of biomarkers, including those for metastatic brain tumors, are presented. Genomic analysis for identifying clinically relevant subtypes of glioblastoma is included. A large number of imaging modalities are detailed to study progression and invasion of gliomas.

Keywords

Molecular medicine Quality of life Tumor diagnosis Tumor therapy Tumor to tumor transfer

Editors and affiliations

  • M.A. Hayat
    • 1
  1. 1., Kean UniversityRoom 213, Library buildingUnionUSA

Bibliographic information

  • DOI https://doi.org/10.1007/978-94-007-1706-0
  • Copyright Information Springer Science+Business Media B.V. 2012
  • Publisher Name Springer, Dordrecht
  • eBook Packages Medicine
  • Print ISBN 978-94-007-1705-3
  • Online ISBN 978-94-007-1706-0
  • About this book
Industry Sectors
Biotechnology
Consumer Packaged Goods
Pharma